Author

R. Delconte

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1 Assay:CITE-seq· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1

Frequent Co-Authors

E. Vivier· 2 shared A. Goubard· 1 shared A. I. Webb· 1 shared A. Krug· 1 shared C. C. Oliveira· 1 shared C. Costa Da Silva· 1 shared C. Harrison· 1 shared D. Olive· 1 shared

Activity by Year

2018-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 25 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

E. Vivier

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity

P.-L. Bernard, R. Delconte, S. Pastor, V. Laletin, C. Costa Da Silva, A. Goubard, E. Josselin, R. Castellano, A. Krug, J. Vernerey, R. Devillier, D. Olive, E. Verhoeyen, E. Vivier, N. Huntington, , G. Guittard

This study shows that deleting CISH enhances NK cell activation and anti-tumor responses in both mice and human cells, suggesting CISH as a therapeutic target for improving NK cell immunotherapy.

bioRxiv · Mar 16, 2021Immunology

Therapeutic blockade of Activin-A improves NK cell function and anti-tumor immunity

J. Rautela, L. F. Dagley, I. S. Schuster, S. Hediyeh-Zadeh, R. Delconte, J. Cursons, R. Hennessy, D. S. Hutchinson, C. Harrison, C. C. Oliveira, E. Vivier, A. I. Webb, M. Degli-Esposti, M. Davis, N. D. Huntington, F. Souza-Fonseca-Guimaraes

This study shows Activin-A inhibits NK cell function, promotes transdifferentiation into ILC1-like cells, and suppresses anti-tumor immunity, with therapeutic blockade improving outcomes.

bioRxiv · Oct 29, 2018 · PreprintImmunology